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OBJECTIVES We aimed to identify periprocedural quantitative coronary angiographic (QCA) variables that
have predictive value on long-term angiographic results and to construct multivariate models
using these variables for postprocedural prognosis.
BACKGROUND Coronary stent implantation has reduced the restenosis rate significantly as compared with
balloon angioplasty in short de novo lesions in coronary arteries .3 mm in size. Although the
postprocedural minimal luminal diameter (MLD) is known to have significant bearing on
long-term angiographic results, no practically useful model exists for prediction of angio-
graphic outcome based on the periprocedural QCA variables.
METHODS The QCA data from patients who underwent Palmaz-Schatz stent implantation for short
(,15 mm) de novo lesions in coronary arteries .3 mm and completed six months of
angiographic follow-up in the four prospective clinical trials (BENESTENT I, BENE-
STENT II pilot, BENESTENT II and MUSIC) were pooled. Multiple models were
constructed using multivariate analysis. The Hosmer-Lemeshow goodness-of-fit test was
used to identify the model of best fit, and this model was used to construct a reference chart
for prediction of angiographic outcome on the basis of periprocedural QCA variables.
RESULTS Univariate analysis performed using QCA variables revealed that vessel size, MLD before and
after the procedure, reference area before and after the procedure, minimal luminal cross-sectional
area before and after the procedure, diameter stenosis after the procedure, area of plaque after the
procedure and area stenosis after the procedure were significant predictors of angiographic
outcome. Using multivariate analysis, the Hosmer-Lemeshow goodness-of-fit test showed that
the model containing percent diameter stenosis after the procedure and vessel size best fit the data.
A reference chart was then developed to calculate the expected restenosis rate.
CONCLUSIONS Restenosis rate after stent implantation for short lesions can be predicted using the variables
percent diameter stenosis after the procedure and vessel size. This meta-analysis indicates that
the concept of “the bigger the better” holds true for coronary stent implantation. Applicability
of the model beyond short lesions should be tested. (J Am Coll Cardiol 1999;34:1067–74) ©
1999 by the American College of Cardiology
Introduction of coronary stenting into the armamentarium
of interventional cardiology marks a distinct milestone in
the history of coronary angioplasty. Although first concep-
tualized by Charles Dotter in 1964 (1), it became a reality
when Jacques Puel (2), followed shortly by Ulrich Sigwart
(3), performed the first human implantations in 1986. The
initial multicenter study by Schatz et al. (4) demonstrated
the safety and efficacy of the implantation of the Palmaz-
Schatz (P-S) coronary stent. This was soon followed by two
randomized trials: BElgian NEtherlands STENT study
(BENESTENT I) (5) and STent REStenosis Study
(STRESS) (6) that compared the P-S stent with balloon
angioplasty. Since the landmark BENESTENT I trial we
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have accumulated enormous data on the use of the P-S
intracoronary stent. Over the years the practice of coronary
stenting has evolved progressively through improvements in
stent design and characteristics as well as in techniques of
optimal deployment. The postprocedural management has
also improved and the problem of stent thrombosis has been
solved to a great extent. However, the problem of restenosis,
although reduced, still exists despite this evolution. Various
factors like use of multiple stents (7–9), stenting of long
lesions (10), total occlusions (7) and small vessels ,3 mm
(7,8), diabetes mellitus (9) and stenting of restenotic lesions
(7,11) have been considered to be the predictors of resten-
osis. We hypothesized that in the cohort of BENESTENT
type lesions, the periprocedural quantitative coronary angio-
plasty (QCA) variables alone, after implantation of the P-S
stent, could predict the restenosis rate at six months. This
meta-analysis of the BENESTENT I, BENESTENT II
pilot, BENESTENT II and Multicenter Ultrasound Stent
In Coronaries (MUSIC) trials was done to verify this idea.
The aims of this analysis were to
1. identify periprocedural QCA variables that have a pre-
dictive value on long-term angiographic results, specifi-
cally the restenosis rate based on a categoric criterion of
diameter stenosis (DS) .50%;
2. construct a variety of multivariate models using these
variables for the prediction of long-term angiographic
outcome;
3. select the model with best fit based on the Hosmer-
Lemeshow goodness-of-fit test; and
4. obtain the most practical model for periprocedural guid-
ance or for postprocedural prognosis, or both.
These trials have been considered together because their
angiographic outcomes have been analyzed using identical
methods of analysis and definitions of the variables in the
same core laboratory.
METHODS
Four clinical trials (BENESTENT I [5], BENESTENT II
pilot [12], BENESTENT II [13,14] and MUSIC [15])
that used the P-S intracoronary stent over a period of seven
years were considered for this meta-analysis. These four
studies were considered together because of their common
design features. Of the four studies, two were prospective
randomized studies and two were prospective observational
studies for new treatment strategies. Only patients with
stable angina pectoris were enrolled in the BENESTENT I
and MUSIC studies, whereas the BENESTENT II pilot
and BENESTENT II trials also recruited patients with
unstable angina. Coronary angioplasty was performed with
stent implantation of native coronary artery lesions ,15 mm in
length (only BENESTENT II included lesions ,18 mm) in
vessels .3 mm that supplied viable myocardium. Patients
with an ostial lesion, a bifurcation lesion or a lesion in a
previously grafted vessel were excluded. Balloon angioplasty
followed by stent implantation was performed according to
standard clinical practice by the femoral approach. The
post-stenting anticoagulation regimen varied as a result of
changes in concepts over time, but all patients received
aspirin after stenting. Use of on-line quantitative angiogra-
phy to optimize stent placement was encouraged in the
BENESTENT II pilot study, and the use increased pro-
gressively during the course of the study. In the MUSIC
study, systematic use of intravascular ultrasound (IVUS)
guidance was undertaken to optimize the results. All pa-
tients had clinical follow-up after one, three and six months
and a follow-up angiogram was obtained at six months.
Angiographic analysis. Three angiograms were obtained
per patient, one immediately before the intervention, one
immediately after and one at follow-up. The off-line anal-
ysis of all angiograms was done at the core laboratory
(Cardialysis, Rotterdam, The Netherlands) using the Car-
diovascular Angiography Analysis System II (CAAS II)
(Pie Medical, Maastricht, The Netherlands), which has
been validated previously (16). For each patient, multiple
matched angiographic views were acquired after intracoro-
nary administration of nitrates. Patients with an unsuccess-
ful procedure or without angiographic follow-up were ex-
cluded from the final analysis. For patients having
multilesion percutaneous transluminal coronary angioplasty,
all lesions were analyzed and each was considered indepen-
dent. To standardize the method of data acquisition and to
ensure exact reproducibility of the angiograms performed
after the intervention and at follow-up, measurements were
made as described earlier (17). The catheter calibration was
based on dimensions of the catheters not filled with contrast
medium (18). A dual type of quantitative analysis was used:
vessel analysis and stent analysis (12). Vessel analysis was
applied to the segment located between two side branches,
and stent analysis was applied to the part actually stented.
This was considered necessary, because most of the vessels
Abbreviations and Acronyms
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taper and as a consequence minimal luminal diameter
(MLD) was found out of the stented area. In each analyzed
segment, mean diameter, MLD and reference interpolated
diameter were determined. New lesions that developed in
the vessel beyond the stented segments were excluded from
the analysis.
Definitions. The reference diameter (RD) was the diam-
eter obtained by an interpolated method, and the lesion
length was defined by the curvature analysis (19,20). Diam-
eter stenosis after stenting was defined as the MLD within
the stent related to the interpolated diameter measured over
the length of the stent. Plaque area was derived from the
reconstructed boundaries. The luminal area measurements
were obtained by a videodensitometric method (21,22) and
included minimal luminal cross-sectional area and percent
area stenosis. To describe negative stenosis where it was
present, mean stent diameter was expressed relative to the
interpolated RD.
Statistical methods. The statistical analysis was done using
the SAS software package (SAS Institute, Cary, North
Carolina). Continuous variables were compared using the
Student t test and the categoric variables by the Fisher exact
test. Multiple QCA variables were tested using univariate
analysis to determine the predictors of long-term angio-
graphic outcome. Using multivariate analysis, multiple
models containing the QCA variables relating to long-term
angiographic outcome were constructed. Considering this
pragmatic approach indexes such as acute gain and late loss
were not included in the models. Also variables accounting
for the differences in the studies were not included in the
models. The models were then tested using the Hosmer-
Lemeshow goodness-of-fit test to choose the most appro-
priate model. In the Hosmer-Lemeshow goodness-of-fit
test, an estimated event probability is calculated from the
observations using a model. These observations are then
sorted in order of their estimated event probability and
divided in approximately 10 groups (g) of about equal size.
The Hosmer-Lemeshow goodness-of-fit statistic is ob-
tained by calculating the Pearson chi-square test from the
2 3 g table of the observed and the expected frequencies.
The greater the p value (smaller the chi-square number) the
better the model fits the data.
Ethical issues. The study was carried out according to the
principles of the declaration of Helsinki. Written informed
consent according to local practice was obtained from every
patient.
RESULTS
A total of 775 patients who underwent coronary angioplasty
with P-S stent implantation and who completed six-month
angiographic follow-up were considered for the meta-
analysis. The baseline characteristics of these patients are
summarized in Table 1. The length of stent used was
15 mm except in BENESTENT II study where 10-mm and
20-mm stents were also used. The stents implanted in
the BENESTENT II pilot and BENESTENT II studies
were heparin-coated. The pharmacotherapy after stenting
consisted of oral vitamin-K antagonist with aspirin in
BENESTENT I and the first three phases of BENESTENT
II pilot trial. In phase IV of the BENESTENT II pilot and
BENESTENT II main study, all patients were treated with a
combination of aspirin and ticlopidine, whereas in the MUSIC
study patients meeting the IVUS criteria of optimal stent
deployment received only aspirin. Online QCA was not used
in the BENESTENT I trial. During the BENESTENT II
pilot trial, its use increased progressively from 53% to 68%
from phase I to phase IV. In addition IVUS guidance for
stenting was also used in a minority of the patients in
BENESTENT II (12%, 8%, 20% and 8% in phase I to IV,
respectively). In the BENESTENT II main study, on-line
QCA was performed for 57% of lesions. In the MUSIC
trial, systematic use of IVUS guidance was made to optimize
stent deployment. The mean balloon pressure used for final
stent deployment was 10 6 8 atm in BENESTENT I.
Inflation pressures .12 atm for dilation after stenting were
applied in 43%, 71%, 67% and 82% of patients, respectively,
from phase I to IV of the BENESTENT II pilot study. The
mean pressures used for final stent deployment in the
BENESTENT II and MUSIC studies were 15 6 3 and
15.8 6 3.3 atm, respectively. The pooled mean RD was
Table 1. Baseline Patient Characteristics
BENESTENT
I
BENESTENT II
Pilot
BENESTENT
II MUSIC
Age (yr) 57 6 9 58 6 10 59 6 11 60 6 9
Male gender (%) 80 84 77 82
CCS class III or IV
angina (%)
54 46 24 43
Diabetes mellitus (%) 7 8 13 11
Previous MI (%) 20 23 25 25
Previous CABG (%) 0 3 2 2
Previous PTCA (%) 2 6 7 9
BENESTENT 5 BElgian NEtherlands STENT study; CABG 5 coronary artery bypass graft surgery; CCS 5 Canadian
Cardiovascular Society; MI 5 myocardial infarction; MUSIC 5 Multicenter Ultrasound Stent In Coronaries study; PTCA 5
percutaneous transluminal coronary angioplasty.
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3.04 mm and the mean RD in the individual trials ranged
from 2.99 mm (BENESTENT I) to 3.16 mm (BENE-
STENT II pilot). The mean length of the lesions dilated
was 8.19 mm. Preprocedural MLD measured 1.10 mm, and
the preprocedural DS was 63.6%. The mean MLD imme-
diately after the procedure increased to 2.69 mm and DS
decreased to 17.7%. The comparative data from the indi-
vidual trials and the pooled mean values are presented in
Table 2. The corresponding measurements calculated by
videodensitometry are shown in the Table 3. Mean area
stenosis decreased from 85% to 7%, and the mean minimal
luminal area improved from 1.15 to 6.28 mm2. The maxi-
mal nominal balloon size used increased gradually (3.40 6
0.40 mm in BENESTENT I to 3.65 6 0.37 mm in
MUSIC), as did the maximal inflation pressures (10.0 6
8.0 atm in BENESTENT I to 15.8 6 3.3 atm in MUSIC).
The mean MLD achieved after the procedure progres-
sively improved from smallest in BENESTENT I to largest
in MUSIC (2.49 mm vs. 2.90 mm, respectively). A corre-
sponding fall in the restenosis rate from 21% to 10% was
observed in these trials. When the mean MLD was com-
pared with the restenosis rate in each trial, a potential linear
relation between the two variables emerged (Fig. 1). Uni-
variate analysis performed using the angiographic variables
to determine the predictor(s) of restenosis revealed that
vessel size, MLD before and after the procedure, reference
area before and after the procedure, minimal luminal cross-
sectional area before and after the procedure, DS after the
procedure, area of plaque before the procedure and area
stenosis after the procedure were significant predictors of
restenosis (Table 4). However, left anterior descending
coronary artery location, stent-artery ratio, maximal balloon
inflation pressure, lesion length, area stenosis and DS before
the procedure were not related significantly to long-term
angiographic outcome. Multiple models were constructed
using the QCA variables in multivariate analysis (Table 5).
Using the Hosmer-Lemeshow goodness-of-fit test, two
appropriate models emerged—one with one variable (MLD
after the procedure) and the other with two variables (vessel
size and percent DS after the procedure) (Table 5). As
MLD after the procedure is a more direct and practical
measurement than percent DS after the procedure, a third
model was constructed replacing percent stenosis with
MLD after the procedure in model II. When tested using
the Hosmer-Lemeshow goodness-of-fit test, this model
showed a lower probability value than the second model,
thereby indicating its inferiority. The observed and expected
restenosis rate on the basis of model II is depicted in Figure
2.
Reference chart. Using the best fit model of DS after the
procedure and vessel size (model II), a chart was developed
Table 2. Quantitative Coronary Angiographic Results by Edge-Detection Method
BENESTENT
I
BENESTENT
II—Pilot
BENESTENT
II MUSIC
Pooled
Mean
Value
25th
Percentile
75th
Percentile
Median
Value
RD pre (mm) 2.99 3.16 2.96 3.09 3.04 2.72 3.33 2.99
Length (mm) 7.03 8.37 8.20 8.19 7.89 6.25 9.22 7.66
MLD pre (mm) 1.08 1.12 1.08 1.13 1.10 0.91 1.27 1.06
MLD post (mm) 2.49 2.77 2.69 2.90 2.69 2.42 2.97 2.68
DS pre (%) 64 64 63 63 63.6 58.0 70.00 64.00
DS post (%) 21 18 16 15 17.7 12.50 22.00 16.6
Stent-artery ratio (%) — 21.26 23.82 26.08 23.52 210.02 3.58 22.69
Restenosis rate (%) 21 12 16 10 — — — —
Columns 2 to 5 show the mean value of each variable in the individual study. Column 6 represents the pooled mean for each variable. Column 9 shows the median value for
each variable in the pooled data. Negative values for stent-artery ratio indicate greater mean stent diameter than reference diameter.
DS 5 diameter stenosis; MLD 5 minimal lumen diameter; RD 5 reference diameter; pre 5 before procedure; post 5 after procedure; other abbreviations as in Table 1.
Table 3. Quantitative Coronary Angiographic Results by Videodensitometry
BENESTENT
I
BENESTENT
II Pilot
BENESTENT
II MUSIC
Pooled
Mean Value
25th
Percentile
75th
Percentile
Median
Value
RA pre (mm2) 7.21 8.00 7.11 7.72 7.47 5.87 8.76 7.06
RA post (mm2) 8.03 9.12 8.13 9.25 8.55 6.93 9.88 8.35
MLCA pre (mm2) 0.87 1.37 1.13 1.32 1.15 0.55 1.59 0.93
MLCA post (mm2) 4.72 7.07 6.54 7.41 6.28 4.80 7.61 6.10
AS pre (%) 88.0 83.0 84.0 82.0 84.7 79.00 92.00 86.50
AS post (%) 41.0 23.0 20.0 20.0 27.2 15.3 37.5 25.00
Columns 2 to 5 show the mean value of each variable in the individual study. Column 6 represents the pooled mean value for each variable. Column 9 shows the median value
for each variable in the pooled data.
AS 5 area stenosis; MLCA 5 minimal lumen cross-sectional area; RA 5 reference area; other abbreviations as in Tables 1 and 2.
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(Table 6 and Fig. 3) that can be used as a ready reference to
estimate expected restenosis rates using immediate postpro-
cedure angiographic variables. The range of the two vari-
ables was divided into 10 groups each. The expected
restenosis rate using model II for the median value of each
range was calculated along with the 95% confidence inter-
vals (CIs) for this particular value. The expected restenosis
rate is given at the top in each cell, and the CI is indicated
at the bottom. For example, for a vessel size of 1.83 to
2.14 mm and postprocedural percent DS of 19.1% to 23.5%,
the expected restenosis rate is 0.44% or 44% (95% CI 32%
to 56%). The cells in the chart marked by an asterisk and
figures in italics indicate that there were no observations in
that range in the actual data set, and the figures mentioned
there are calculated by extrapolation from the model.
Caution must be exercised while using the reference chart in
these ranges.
DISCUSSION
The multivariate analysis of QCA variables pooled from the
four trials of P-S stent implantation for short de novo
lesions in coronary arteries .3.0 mm revealed that MLD
after the procedure, vessel size and percent DS after the
procedure procedure were the strongest predictors of the
long-term angiographic outcome. The model containing
vessel size and percent DS after the procedure provide the
best fit to the data, thus highlighting the importance of early
results.
Figure 1. Potential linear relation between MLD after the proce-
dure and observed restenosis rate in the four trials.
Table 4. Quantitative Coronary Angiographic Variables—
Univariate Analysis of Predictors for Long-Term Outcome
Variable p Value
Vessel size , 0.001
MLD post , 0.001
RA pre , 0.001
RA post , 0.001
MLCA post , 0.001
MLCA pre 0.001
MLD pre 0.002
DS post 0.006
Plaque area pre 0.015
AS post 0.035
LAD location 0.160
Stent-artery ratio 0.172
Lesion length 0.220
Plaque area post 0.452
Maximal balloon inflation pressure 0.474
AS pre 0.812
DS pre 0.917
LAD 5 left anterior descending coronary artery; RA 5 reference area; other
abbreviations as in Tables 2 and 3.
Table 5. Multivariate Models Using Quantitative Coronary
Angiographic Variables
Variable Coefficient SE p Value
Model I
Intercept 2.67
MLD post 21.68 0.28 ,0.001
Hosmer-Lemeshow goodness-of-fit statistic 10.328;
p 5 0.243.
Model II
Intercept 1.32
Vessel size 21.34 0.25 ,0.001
% DS post 0.05 0.001 ,0.001
Hosmer-Lemeshow goodness-of-fit statistic 8.705;
p 5 0.368.
Model III
Intercept 3.45
Vessel size 20.59 0.26 0.025
MLD post 21.31 0.30 ,0.001
Hosmer-Lemeshow goodness-of-fit statistic 13.970;
p 5 0.083.
SE 5 standard error; other abbreviations as in Table 2.
Figure 2. Observed and expected restenosis rate calculated using
model II in the 10 patient groups on the basis of the Hosmer-
Lemeshow goodness-of-fit test.
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The difference between BENESTENT I and MUSIC.
The most conspicuous observation emerging from these
trials is the improvement in MLD after the procedure
(2.49 mm in BENESTENT I and 2.90 mm in MUSIC)
and the reduction in the restenosis rate from 21% in
BENESTENT I to 10% in MUSIC, thus supporting the
concept “the bigger the better” in a very homogeneous
population treated with intracoronary stent implantation.
Introduction of on-line QCA and IVUS guidance are
potentially responsible for this improvement. Heparin coat-
ing of the stents was tried in the BENESTENT II pilot and
the BENESTENT II study to circumvent the problem of
subacute stent thrombosis, which emerged as the main
hurdle to overcome in coronary stent implantation since the
BENESTENT I and STRESS studies. Analysis of both
these studies made it clear that although heparin coating did
reduce the subacute thrombosis rate significantly, it had no
effect on long-term outcome and restenosis rate (12,14).
Applicability of “the bigger the better.” Kuntz et al. (23)
first introduced this concept and demonstrated that it holds
true irrespective of the device used for coronary angioplasty
(24). They also suggested that a variety of other factors
independently modulate restenosis superimposed on the
platform of early results. However, there is significant
evidence suggesting that this concept is device-specific and
does not hold true for debulking techniques such as direc-
tional coronary atherectomy and excimer laser therapy
(25,26).
Reasons for the difference. Three factors may have led to
superior results, including the use of online QCA, high
pressure dilation and IVUS guidance. Online digital auto-
mated edge detection QCA systems decrease measurement
variability in comparison with visual assessment of coronary
artery dimensions or hand-held callipers (27,28). Accurate
Table 6. Reference Chart Generated Using Model II
Percent Diameter Stenosis After Procedure
Vessel size
(mm) 1.5–5.9 5.9–10.3 10.3–14.7 14.7–19.1 19.1–23.5 23.5–27.9 27.9–32.3 32.3–36.7 36.7–41.1 41.1–45.5
1.83–2.14 0.24* 0.28 0.33 0.38 0.44 0.49 0.55 0.61 0.66* 0.71*
0.15–0.36 0.19–0.40 0.23–0.45 0.28–0.50 0.32–0.56 0.37–0.62 0.41–0.69 0.44–0.75 0.48–0.80 0.51–0.85
2.14–2.45 0.17 0.21 0.25 0.29 0.34 0.39 0.45 0.50 0.56 0.62*
0.11–0.26 0.14–0.28 0.18–0.32 0.22–0.37 0.26–0.42 0.30–0.49 0.34–0.57 0.37–0.64 0.40–0.71 0.43–0.78
2.45–2.76 0.12 0.15 0.18 0.21 0.25 0.30 0.35 0.40 0.46 0.51*
0.08–0.18 0.11–0.20 0.14–0.22 0.17–0.26 0.21–0.30 0.24–0.37 0.27–0.44 0.29–0.52 0.32–0.61 0.35–0.68
2.76–3.07 0.08 0.10 0.12 0.15 0.18 0.22 0.26 0.31 0.36 0.41
0.05–0.12 0.07–0.14 0.10–0.16 0.13–0.18 0.15–0.22 0.18–0.27 0.20–0.33 0.22–0.41 0.24–0.49 0.26–0.58
3.07–3.38 0.06 0.07 0.09 0.11 0.13 0.16 0.19 0.23 0.27 0.32
0.03–0.09 0.05–0.10 0.06–0.11 0.08–0.13 0.10–0.16 0.12–0.20 0.14–0.25 0.15–0.32 0.17–0.39 0.19–0.48
3.38–3.69 0.04 0.05 0.06 0.07 0.09 0.11 0.13 0.16 0.20 0.23
0.02–0.07 0.03–0.07 0.04–0.09 0.05–0.10 0.06–0.12 0.08–0.15 0.09–0.19 0.10–0.25 0.12–0.31 0.13–0.38
3.69–4.00 0.03 0.03 0.04 0.05 0.06 0.07 0.09 0.11 0.14 0.17
0.01–0.05 0.02–0.06 0.02–0.07 0.03–0.08 0.04–0.10 0.05–0.12 0.05–0.15 0.06–0.19 0.07–0.24 0.08–0.30
4.00–4.31 0.02* 0.02 0.03 0.03 0.04 0.05 0.06 0.08 0.10* 0.12*
0.01–0.04 0.01–0.04 0.01–0.05 0.02–0.06 0.02–0.08 0.03–0.09 0.03–0.12 0.04–0.15 0.05–0.19 0.05–0.24
4.31–4.62 0.01* 0.01* 0.02* 0.02* 0.03 0.03 0.04 0.05* 0.07* 0.08*
0.00–0.03 0.01–0.03 0.01–0.04 0.01–0.05 0.01–0.06 0.02–0.07 0.02–0.09 0.02–0.12 0.03–0.15 0.03–0.19
4.62–4.93 0.01* 0.01* 0.01* 0.01* 0.02 0.02* 0.03* 0.04* 0.04* 0.05*
0.00–0.02 0.00–0.03 0.00–0.03 0.01–0.04 0.01–0.05 0.01–0.06 0.01–0.07 0.01–0.09 0.02–0.11 0.02–0.15
The cells marked with numbers in italics and an asterisk indicate the range without actual observations in the data set. Cells with bold numbers indicate the range with actual
observations.
Figure 3. Three-dimensional bar diagram representing the refer-
ence chart. The lower the vessel size and the higher the DS after
the procedure, the higher the expected restenosis rate.
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assessment of dimensions is important to guide sizing of
balloon and other devices. Note that online QCA was not
used during the BENESTENT I study but was used increas-
ingly during the course of the BENESTENT II pilot study.
The concept of optimal stent deployment using high
pressure dilation was proposed by Colombo et al. (29–33).
Using IVUS they demonstrated that most of the angio-
graphically satisfactory stent deployments were in fact far
from being optimal and proposed the use of high pressure
intrastent dilation and the use of IVUS to optimize stent
placement. It was also noted that high pressure dilation with
an appropriately sized balloon was better than using an
oversized balloon, because the rate of complications like
coronary rupture was higher with oversized balloons. The
stent deployment strategy used in the BENESTENT I trial
was according to the strategy in vogue (4), and only
moderate pressure inflations were used for postdilation of
the stents. The use of high pressure intrastent dilations became
routine during subsequent trials. Although the debate about
benefits of high pressure intrastent dilations has continued
(34), a recent retrospective study by Goldberg et al. (33) has
shown that the aggressive stent implantation techniques were
not associated with increased late loss or restenosis and the
above meta-analysis confirms this. Bauters et al. (35) have also
demonstrated that high pressure inflation in the P-S stent was
an independent predictor of lower late lumen loss. The results
of this meta-analysis indicate that in the MUSIC study high
pressure dilation was one of the factors associated with a
reduction in the restenosis rate.
The role of IVUS imaging in the era of high pressure
stent deployment remains to be clearly established. A recent
study by Akiyama et al. (36) showed that, despite high
pressure dilation, 33% of the lesions required additional
treatment when assessed by IVUS. The preliminary results
of the Angiography Versus Intravascular Ultrasound Directed
Coronary Stent Placement (AVID) study (37) also support
this; however, the long-term implications of this finding have
yet to be established. The present study indicates that IVUS-
guided optimal stent deployment was one of the important
factors responsible for the improved results.
Left anterior descending coronary artery location. Phil-
lips et al. (38) and Wong et al. (39) have demonstrated that
stent implantation in the proximal left anterior descending
coronary artery is associated with a greater reduction in the
restenosis rate as compared with implantation elsewhere in
the coronary tree. In contrast, Bauters et al. (35) and the
current univariate analysis support the notion that after stent
implantation, left anterior descending coronary artery loca-
tion ceases to be a predictor of restenosis.
Can we equate the results of off-line QCA with on-line
QCA? In the present study the results of offline QCA were
used to construct the multivariate models, whereas the
best-fit model, which was used to build the reference chart,
used the variables of percent DS after the procedure and
vessel size. Previous studies (40) have demonstrated that the
geometric variables of MLD and obstruction diameter, as
measured by off-line and on-line QCA systems, respec-
tively, show good correlation. The correlation between
interpolated and relative variables, like interpolated RD and
percent DS, although acceptable, was lower (r 5 0.76) than
that of the geometric variables. The difference in the derived
variables was due to the fact that the two systems use
different definitions to calculate the relative variables. Avail-
ability of second-generation QCA systems like CAAS II,
which can be used both online and offline, should resolve
this problem. Other second-generation QCA systems like
CMS, QANSAD, AWOS, Cardio 500 and Angioimage
have been shown to be more precise than the first-
generation systems and were validated in vitro by Hausleiter
et al. (41). However, intersystem variability needs to be
established before these results from CAAS II can be
extrapolated to other systems.
Can the results be generalized? The multivariate models
were developed using the data obtained by the use of the
P-S stent, and the applicability of the same to other stents
is not clear. Several ongoing or recently completed multi-
center randomized trials comparing stents like GR II (42)
(second-generation), AVE Micro (43) (SMART [Study of
AVE Micro Stent ability to limit Restenosis Trial]), Cardiocoil
(RACE), ACS Multilink (ASCENT [ACS Multilink Clini-
cal Equivalence Trial]), NIR (NIRVANA [NIR vs. Palmaz-
Schatz]), Radius (SCORES [Stent Comparative Restenosis
Trial]) and Wallstent to the P-S stent will tell us about the
equivalence of these stents to the P-S stent. Meanwhile, it
would be interesting to apply the reference chart to the data
from the WEST (Western European Stent Trial) I (44) and
WEST II (45) trials (MULTI-LINK stent implanted under
IVUS guidance) to find out the applicability of this type of
reference chart. The current model is based on the implan-
tation of stents in short de novo lesions in native coronary
arteries .3 mm in diameter, and its applicability remains to
be tested in cohorts outside this restricted framework.
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